Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria

Hemasphere. 2023 Sep 7;7(10):e954. doi: 10.1097/HS9.0000000000000954. eCollection 2023 Oct.

Minna Harmanen¹, Tuula Klaavuniemi², Marc Sorigue³, Madiha Khan¹, Roosa Prusila^{4

5}, Esa Kari⁶, Erika Alanne⁷, Aino Rajamäki^{1

6

8}, Kaisa Sunela^{6

9}, Arja Jukkola⁶, Esa Jantunen^{10

11}, Juan-Manuel Sancho³, Sanna Ketola⁸, Hanne Kuitunen⁵, Tuomas Selander¹², Aino Rönkä¹³, Outi Kuittinen^{1

5}

¹ Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
² Department of Oncology, Mikkeli Central Hospital, Southern Savonia Municipality District, Mikkeli, Finland.
³ Department of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain.
⁴ Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
⁵ Cancer Center and Medical Research Center, Oulu University Hospital, Oulu, Finland.
⁶ Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
⁷ Department of Oncology and Radiotherapy, Turku University Hospital, Western Finland, Cancer Center, Turku, Finland.
⁸ Department of Oncology, Hospital Nova of Central Finland, Jyväskylä, Finland.
⁹ Finnish Medicines Agency, Tampere, Finland.
¹⁰ Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, North Carelia Central Hospital, Joensuu, Finland.
¹¹ Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
¹² Science Service Center, Kuopio University Hospital, Kuopio, Finland.
¹³ Department of Oncology and Radiotherapy, Kuopio University Hospital, Kuopio, Finland.

No abstract available